ATXS vs BMY · rev $706.0K vs P/E 17, rev $24.46B
Astria Therapeutics Inc (ATXS) versus Bristol-Myers Squibb Company (BMY) — a side-by-side from cached financials, not a winner call.
Astria Therapeutics Inc (ATXS) is a biotechnology company listed on US.
Bristol-Myers Squibb Company (BMY) is a drug manufacturers - general company listed on US. It is led by Christopher S. Boerner Ph.D..
Latest reported ATXS revenue for 2025-09-30 was $706.0K. Net income was -$98.4M. ATXS currently screens at market cap $382.1M.
Latest reported BMY revenue for 2026-06-30 was $24.46B. Net income was $5.99B. BMY currently screens at market cap $95.36B and trailing P/E 17.5.
ATXS currently screens at market cap $382.1M. BMY currently screens at market cap $95.36B and trailing P/E 17.5.
Not investment advice. Open the ATXS and BMY stock pages for the full models.
Not investment advice.